Public Policy Solutions, a policy advocacy organization focused on health care and economic issues, said some hospitals are exploiting the federal 340B Drug Pricing Program in ways that increase costs for patients and taxpayers, while calling for greater transparency and reforms to ensure the program benefits underserved populations as intended.
"340B has spiraled into a shady, opaque system that hospitals leverage as a cash cow while patients and taxpayers foot the bill," the group said in a post on X. "Hospitals' exploitation of the program, including through duplicate discounts, has forced drug makers to take drastic measures. Reform and transparency are long overdue."
The organization made the remarks in response to Eli Lilly's requirement that hospitals submit 340B claims data by June 1 or risk losing access to certain discounts. Public Policy Solutions argued that duplicate discounts and other practices have contributed to growing tensions between pharmaceutical manufacturers and covered entities participating in the program.
The 340B Drug Pricing Program, established in 1992, requires pharmaceutical manufacturers participating in Medicaid to provide outpatient drugs to eligible hospitals and other covered entities at discounted prices. Those providers can then seek reimbursement from insurers at higher rates, with the savings intended to support care for low-income and underserved patients. The program has grown substantially over the past decade, with discounted drug purchases reaching tens of billions of dollars annually, according to the Health Resources and Services Administration.
Critics argue that savings generated through the program are not always passed on to patients and that some hospitals have benefited financially from the discounts without demonstrating corresponding increases in charity care or reduced drug costs for vulnerable populations.
Ongoing debates have also focused on program expansion, contract pharmacies and efforts to ensure benefits reach the patients the program was designed to serve. State-level efforts have also emerged to address pricing differences for 340B patients compared with other patients, according to Magnolia Market Access.
Public Policy Solutions advances policy proposals aimed at strengthening national security, expanding economic opportunity and empowering Americans. The organization regularly engages in health care policy debates and advocates for reforms focused on transparency, accountability and consumer impacts.
Alerts Sign-up